One billion retail oral antithrombotic drugs are "emergency"!

A few days ago, the official website of the State Food and Drug Administration showed that Shaanxi Buchang High-tech Pharmaceuticals was approved for imitating Rivaroxaban tablets for production in Category 4 and deemed to have been reviewed, becoming the company’s first approved antithrombotic drug; in addition, Suzhou Dawnrays Pharmaceuticals and Lepu Pharmaceutical's rivaroxaban tablets were accepted by the CDE when they submitted their application for marketing in generic 4 categories

The antithrombotic drug market is making waves again! Bayer wins the throne of "first brother"

Sales of terminal antithrombotic drugs in physical pharmacies in cities in China in recent years (unit: 100 million yuan)

Source: Mi Nei.

A few days ago, the official website of the State Food and Drug Administration showed that Shaanxi Buchang High-tech Pharmaceuticals was approved for imitating Rivaroxaban tablets for production in Category 4 and deemed to have been reviewed, becoming the company’s first approved antithrombotic drug; in addition, Suzhou Dawnrays Pharmaceuticals and Lepu Pharmaceutical's rivaroxaban tablets were accepted by the CDE in the application of generic 4 types of rivaroxaban.

From the perspective of TOP10 manufacturers, Bayer's market share surpassed Sanofi to win the "first brother" throne, Shenzhen Xinlitai Pharmaceutical Co.

Oral antithrombotic drugs approved for marketing since 2021

Source: Meinenet MED2.

Since the beginning of this year, a total of 6 oral antithrombotic drugs have been approved for marketing.

One billion retail oral antithrombotic drugs "emergency", soaring 500% varieties hit the TOP10

2020 China's urban physical pharmacies terminal anti-thrombotic chemical products TOP10 (unit: 100 million yuan)

Source: Mi Nei.

Note: Sales of less than 100 million yuan will be displayed as "*"

From the perspective of product TOP10, the market share of clopidogrel bisulfate tablets, aspirin enteric-coated tablets, and rivaroxaban tablets together accounted for more than 70%, and the market concentration was high

Sales of Clopidogrel Bisulfate Tablets in Chinese Urban Entity Pharmacies in Recent Years (Unit: 100 million yuan)

Source: Mi Nei.

Clopidogrel bisulfate tablets won the exclusive bid for 4+7 Central Procurement, CITIC Litai, and 4+7 Expanded Central Procurement, Sanofi, CSPC Ouyi Pharmaceutical, and Lepu Pharmaceutical won the bid

It is worth noting that among the TOP10 products, apixaban tablets and ticagrelor tablets are the third batch of collectively collected varieties, and rivaroxaban tablets and dabigatran etexilate capsules are the fifth batch of collectively collected varieties.

As centralized procurement enters the normalization stage, the number of included varieties will increase.

Three major products of pharmaceutical companies "get together", Hausen, Yangtze River.

Source: Meinenet MED2.

Since the beginning of this year, a total of 9 oral antithrombotic drugs have been reported for production and are under review and approval

4 products of clopidogrel bisulfate aspirin tablets, selepagram tablets, ticagrelor dispersible tablets, and idoxaban tosylate tablets have not been approved for generic drugs, Jiangsu Hausen Pharmaceutical Group, Yangzijiang Pharmaceutical Group Guangzhou Hairui Pharmaceuticals, Hainan Simcere Pharmaceuticals and many other companies are under review and approval
.

Source: official website of the State Food and Drug Administration, Mynet database, etc.

Please correct me if there are any errors or omissions
.